NCT03506815View on ClinicalTrials.gov

Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

May 14, 2020

Study Completion Date

June 14, 2020

Conditions
Upper Extremity Deep Vein ThrombosisCentral Venous Catheter ThrombosisCancer
Interventions
DRUG

Rivaroxaban 10 MG

Rivaroxaban 10mg po daily x 90 (+/- 3 days)

Trial Locations (1)

K1H 8L6

The Ottawa Hospital General Campus, Ottawa

Sponsors
All Listed Sponsors
collaborator

Queen Elizabeth II Health Sciences Centre

OTHER

collaborator

University of Alberta

OTHER

collaborator

Hamilton Health Sciences Corporation

OTHER

lead

Ottawa Hospital Research Institute

OTHER